AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25359291
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and adalimumab treatment
Trial: 25359642
Drug: Monitoring (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring (oral hygiene instruction, applying or prescribing fluoride or varnish, or both)
Trial: 25359988
Drug: Rituximab and
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab and chemotherapy (6 5-day cycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intrathecal therapy; Rituximab given before each cycle and twice as maintenance, total of 8 doses)
Trial: 25359988
Drug: Rituximab and
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab and chemotherapy
Trial: 25359994
Drug: Cytokine pathway
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine pathway treatment targeting STAT3
Trial: 25360888
Drug: 14 SNPs
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 SNPs previously suggested to influence aspirin efficacy
Trial: 25361625
Drug: Thalidomide (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (starting dose 200 mg/day, escalated to a maximum of 1,000 mg/day) combined with TACE
Trial: 25361837
Drug: Individualised DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised DAPT guided by MEA (treatment for HPR to ADP with prasugrel or ticagrelor, clopidogrel reloading)
Trial: 25362970
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily until progression or unacceptable toxicities
Trial: 25363606
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg once daily for 4 weeks
Trial: 25363606
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg added to tamsulosin after 4 weeks for patients with residual symptoms
Trial: 25363606
Drug: Predictive factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive factors for solifenacin add-on therapy
Trial: 25363997
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT) of warfarin, aspirin, and clopidogrel
Trial: 25363997
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (DT) of warfarin and single antiplatelet agent (aspirin or clopidogrel)
Trial: 25363997
Drug: Dual-antiplatelet therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-antiplatelet therapy (DAPT) of aspirin and clopidogrel
Trial: 25366688
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m², once every 3 weeks)
Trial: 25366688
Drug: No DTCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No DTCs after treatment with docetaxel
Trial: 25369108
Drug: Lanreotide 120
RxNorm normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 120 mg, subcutaneously every 4 weeks for 6 months
Trial: 25369558
Drug: Paired daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paired daily spontaneous awakening trials (SATs) and spontaneous breathing trials (SBTs) in collaborative units.
Trial: 25369725
Drug: Cognitive-behavioral therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapies tailored to caregiver thinking patterns
Trial: 27899756
Drug: NOAC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC treatment
Trial: 25372029
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPT) with SP and SP-PQ
Trial: 25373390
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text messages sent as an adjunct to group Cognitive Behavioral Therapy (CBT) for depression.
Trial: 25374341
Drug: Olaparib 400
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 400 mg orally twice daily until disease progression or drug intolerance
Trial: 25374386
Drug: Antithrombotic agents
RxNorm normalized name: ANTITHROMBOTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic agents initiated in the prehospital phase
Trial: 25374386
Drug: Any GP
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any GP IIb/IIIa inhibitor
Trial: 25374386
Drug: Dual combination
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual combination of ASA+(clopidogrel/prasugrel)
Trial: 25374386
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of five drug classes (ASA, P2Y12 antagonists, statin, beta blocker, ACE-I/ARB)
Trial: 25376618
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide LAR (60 mg every 4 weeks)
Trial: 25377157
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral panobinostat (single dose)
Trial: 25377157
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral panobinostat (thrice weekly)
Trial: 25377177
Drug: Current standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard mycobacterial growth indicator tube (MGIT) drug susceptibility tests
Trial: 25377187
Drug: Prophylactic infusions
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic infusions of FXIII concentrate (human) 40 IU kg(-1) every 4 weeks for 12 months
Trial: 25377187
Drug: Prophylactic infusions
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic infusions of FXIII concentrate (human)
Trial: 25380183
Drug: LGX818 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGX818 (300 mg daily)
Trial: 25380636
Drug: Farletuzumab (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Farletuzumab (administered by intravenous injection, dose escalation planned in 4 cohorts: 50, 100, 200, and 400 mg/m(2))
Trial: 25380654
Drug: L-H status
RxNorm normalized name: Belagenpumatucel-L (NCI H-520)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-H status (combined Lauren classification and HER2 status)
Trial: 25380654
Drug: L-H status
RxNorm normalized name: Belagenpumatucel-L (NCI H-520)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-H status vs Lauren classification
Trial: 25381131
Drug: Vosaroxin (80-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vosaroxin (80-90 mg/m²) plus cytarabine (schedule A: 400 mg/m²/day, days 1-5; schedule B: 1 g/m²/day, days 1-5)
Trial: 25382351
Drug: Intensive multifactorial
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive multifactorial therapy (IT)
Trial: 25384705
Drug: Carbon ion
RxNorm normalized name: CARBON ION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon ion irradiation, median dose 36 Gy (RBE), range 36-51 Gy (RBE)
Trial: 25385094
Drug: Faldaprevir (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir (240 mg QD for 8 days following a 480-mg loading dose) with methadone
Trial: 25385094
Drug: Faldaprevir (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir (240 mg QD for 8 days following a 480-mg loading dose) with buprenorphine-naloxone
Trial: 25385099
Drug: Ethinylestradiol (EE)
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinylestradiol (EE) and Levonorgestrel (LNG) coadministered with 240 mg faldaprevir QD
Trial: 25385409
Drug: Hyperglycaemia (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (plasma glucose 16 mmol/l)
Trial: 25386899
Drug: Minimal Intervention
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Intervention Group (MIG) - goal to increase child's activity to 6000 pedometer steps/day above baseline, daily monitoring by parents
Trial: 25387993
Drug: Septal reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Septal reduction therapy (septal myectomy or alcohol septal ablation)
Trial: 25387993
Drug: Endoscopic intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic intervention and medical therapy for hypertrophic cardiomyopathy
Trial: 25388099
Drug: Collagenase clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase clostridium histolyticum (CCH) 0.58 mg, intralesional injections, administered in cycles of two injections 24-72 hours apart, repeated after 6 weeks for ≤4 cycles.
Trial: 25388099
Drug: Collagenase clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase clostridium histolyticum (CCH) 0.58 mg, intralesional injections.
Trial: 25388167
Drug: PF-04449913 640
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 640 mg once daily
Trial: 25388167
Drug: PF-04449913 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 320 mg once daily
Trial: 25388167
Drug: PF-04449913 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 80 to 320 mg once daily
Trial: 25389254
Drug: Booster vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccination for HCWs with anti-HBs <12 mIU/mL
Trial: 25389443
Drug: Zembrin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zembrin 25 mg daily for 3 weeks
Trial: 25392936
Drug: Hyperfiltering adolescents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfiltering adolescents with T1D (GFR ≥ 135 ml/min/1.73 m²)
Trial: 25392936
Drug: Normofiltering adolescents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normofiltering adolescents with T1D (GFR < 135 ml/min/1.73 m²)
Trial: 25393520
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy (n = 118)
Trial: 25393520
Drug: Daily therapy
RxNorm normalized name: Konsyl Daily Therapy Fiber Laxative 625mg Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily therapy (n = 99)
Trial: 25393536
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d omega-3 acid ethyl esters (P-OM3) for 8 weeks
Trial: 25393640
Drug: Liraglutide (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (0.6 mg/d for 2 weeks, followed by 1.2 mg/d) in addition to metformin (1500 mg/d)
Trial: 25393648
Drug: Vorinostat 400
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 400 mg orally once daily for 14 days
Trial: 25394029
Drug: Maraviroc (MVC)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc (MVC) plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs)
Trial: 25394093
Drug: LPV/r monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r monotherapy OD (LPVrMOD)
Trial: 25394116
Drug: CD4 cell
RxNorm normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4 cell count increase during treatment
Trial: 25394136
Drug: Immunoglobulin at
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin at birth and complete vaccine schedule during the first six months of life
Trial: 25394136
Drug: Immunoglobulin and
RxNorm normalized name: Immunoglobulin G1-kappa/lambda, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279) and HAVCR2 (hepatitis A virus cellular receptor 2, T cell immunoglobulin and mucin domains family member 3, TIM3, TIM-3, TIMD3, CD366)], humanized and Ho
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin and complete vaccine schedule
Trial: 25395260
Drug: Kidney transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney transplantation from HBsAg(+) donors with lamivudine in combination with HBV immunoglobulin
Trial: 25395425
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy plus IFRT
Trial: 25395429
Drug: Dinaciclib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib at 30 mg/m²
Trial: 25395429
Drug: Dinaciclib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib at 40 mg/m²
Trial: 25395429
Drug: Dinaciclib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib at 50 mg/m²
Trial: 25396060
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (25(OH)D levels <20 ng/mL)
Trial: 25397516
Drug: DRV/COBI 800/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/COBI 800/150 mg qd plus two fully active N[t]RTIs
Trial: 25397527
Drug: etravirine (ETR)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: etravirine (ETR) 200 mg bid with an optimised background regimen (BR) excluding DRV/r or NRTIs only
Trial: 25398082
Drug: Training of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training of unlicensed healthcare providers in zinc treatment and diarrhoea management
Trial: 25399249
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy with adaptive difficulty levels
Trial: 25399779
Drug: Levosimendan (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (administered immediately after anaesthesia induction)
Trial: 25399779
Drug: Levosimendan (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (administered later after postoperative ICU admission)
Trial: 25400468
Drug: Neoadjuvant continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy followed by laparoscopic mesorectal excision.
Trial: 25400468
Drug: Withholding adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding adjuvant chemotherapy after complete response following standard neoadjuvant chemoradiotherapy and laparoscopic mesorectal excision.
Trial: 25402221
Drug: Deferasirox 30
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox 30 mg/kg/d
Trial: 25402488
Drug: (131)I-CLR1404, 370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131)I-CLR1404, 370 MBq single injection
Trial: 25402488
Drug: (131)I-CLR1404, 740
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131)I-CLR1404, 740 MBq predicted administration
Trial: 25403209
Drug: 3.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Trial: 25403209
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Trial: 25403209
Drug: 0.3 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Trial: 25403209
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IL-15 (rhIL-15) administration
Trial: 25403217
Drug: Atu027 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atu027 (10 escalating doses, 0.336 mg/kg, intravenous infusions twice per week during a 28-day cycle)
Trial: 25403830
Drug: vosaroxin 72
RxNorm normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vosaroxin 72 mg/m² d 1, 4
Trial: 25403830
Drug: vosaroxin 72
RxNorm normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vosaroxin 72 mg/m² d 1, 8, 15
Trial: 25403830
Drug: vosaroxin 72
RxNorm normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vosaroxin 72 mg/m² d 1, 8
Trial: 25403830
Drug: vosaroxin 90
RxNorm normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vosaroxin 90 mg/m² d 1, 4
Trial: 25404094
Drug: Belinostat (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belinostat (1000 mg/m² intravenously ×5 days of a 21-day cycle)
Trial: 25404412
Drug: QuantiFERON(®)-TB GOLD
RxNorm normalized name: QUANTIFERON-TB GOLD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QuantiFERON(®)-TB GOLD (QFT-G)
Trial: 25404952
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of LY2811376
Trial: 25404952
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of LY2811376
Trial: 25405351
Drug: Baminercept (lymphotoxin-beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baminercept (lymphotoxin-beta receptor-immunoglobulin fusion protein)
Trial: 25405614
Drug: 14-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day antibiotic therapy during acute exacerbations
Trial: 25405724
Drug: Chloroquine by
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine by directly observed therapy
Trial: 25405724
Drug: Antibody response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antibody response to merozoite surface protein 1 (MSP-1)
Trial: 25408112
Drug: Angiopoietin-2 concentrations
RxNorm normalized name: Immunoglobulin G1 Fab fragment, bispecific, anti-(human vascular endothelial growth factor A and angiopoietin 2) (human monoclonal RO7250284 γ1-chain), disulfide with human monoclonal RO7250284 κ-chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiopoietin-2 concentrations at discharge above 2,500 pg/ml
Trial: 25408662
Drug: lanreotide Autogel(®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanreotide Autogel(®) 120 mg, administered as monthly deep-subcutaneous injections
Trial: 25408662
Drug: octreotide long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: octreotide long-acting release (LAR) 30 mg monthly
Trial: 25408662
Drug: chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy treatment with cisplatinum-etoposide
Trial: 25409372
Drug: AAV8 vector
RxNorm normalized name: Recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase
DrugBank: Avalotcagene ontaparvovec (DB16796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV8 vector gene therapy (high dose: 2×10(12) vector genomes per kg)
Trial: 25409372
Drug: AAV8 vector
RxNorm normalized name: Recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase
DrugBank: Avalotcagene ontaparvovec (DB16796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV8 vector gene therapy (high dose)
Trial: 25409372
Drug: AAV8 vector
RxNorm normalized name: Recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase
DrugBank: Avalotcagene ontaparvovec (DB16796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV8 vector gene therapy
Trial: 25411597
Drug: Ipragliflozin 25
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 25 mg
Trial: 25413133
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of NO and oxygen
Trial: 25415228
Drug: MCT1/2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT1/2 inhibitor (AR-C155858)
Trial: 25415228
Drug: Oligomycin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligomycin A (inhibitor of mitochondrial ATP synthase)
Trial: 25416418
Drug: Health care
RxNorm normalized name: Health Care Lancing Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health care providers' awareness of treatment burden
Trial: 25416753
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of wild-type A(H1N1)pdm09 virus at an optimal dose of 10(7) tissue culture infectious dose 50.
Trial: 25416753
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of wild-type A(H1N1)pdm09 virus.